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Abstract 6 
Background: Total knee arthroplasty (TKA) is an effective procedure for relieving 7 
pain and restoring function in osteoarthritis, with a significant proportion of 8 
patients having severe disease bilaterally. However, although there are differences 9 
in patient selection criteria for bilateral procedures, there is no consensus 10 
regarding the optimal timing for bilateral TKA. The aim of this study is to compare 11 
rates, causes of revision and 30-day mortality between simultaneous and staged 12 
bilateral TKA using data from the Australian Orthopaedic Association National Joint 13 
Replacement Registry (AOANJRR). 14 
Methods: Data for over 36,000 bilateral TKAs was collected from September, 1999 15 
to December, 2015. Rates and causes of revision and 30-day mortality rate were 16 
obtained for simultaneous bilateral and staged procedures with intervals of 1 day–17 
6weeks, 6weeks–3months and 3months–6months. Yearly cumulative percent 18 
revision (CPR) or survival (CPS) with 95% confidence intervals calculated by the 19 
Kaplan-Meier method and adjusted hazard ratios were used for comparisons.   20 
Results: There was no significant difference between revision rates or reasons for 21 
revision between staged bilateral and simultaneous TKA (HR 1.09 (95% CI 0.85-22 
1.40; p=0.511) for 1day–6weeks, 0.93 (95% CI 0.77-1.14; p=0.494) for 6weeks–23 
3months, and 1.10 (95% CI 0.98-1.23; p=0.115) for 3months–6months). The most 24 
common reasons for revision were loosening/lysis and infection. The 30-day 25 
mortality rates were lower in the 6weeks-3months group than simultaneous 26 
bilaterals (p=0.007).  27 
Conclusion: This study demonstrates that simultaneous and staged bilateral TKA 28 
have similar rates of revision over the medium term but that 30-day mortality is 29 
reduced in the 6weeks-3months group.  30 
Word count: 249/250 31 
Keywords: Registry; primary: bilateral knees; mortality; survivorship; revision 32 
 33 
Funding: This research did not receive any specific grant from funding agencies in 34 
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Introduction 37 
Total knee arthroplasty (TKA) is a highly successful procedure for relieving pain and 38 
restoring function in severe osteoarthritis of the knee joints. The prevalence of 39 
bilateral knee osteoarthritis has been shown to be as high as 5% [1]. A number of 40 
studies have evaluated the need for a contralateral TKA after the first TKA. Ritter et 41 
al. [2] reported that when the contralateral knee was diagnosed with osteoarthritis 42 
at the time of the first TKA, the second TKA was required within 10 years in 37% of 43 
patients. Mont et al. [3] reported that 23% of patients scheduled for unilateral TKA 44 
had severe symptoms in the contralateral knee, and 93% underwent contralateral 45 
TKA within the follow-up time of the study (minimum of 5 years). 46 
Controversies in timing of bilateral TKA for patients with arthritis in both knees are 47 
far from resolved. The safety of simultaneous bilateral TKA remains a concern [4-48 
6]. There are reports of increased perioperative complications, including 49 
pulmonary embolism, deep vein thrombosis, cardiac, neurologic and wound 50 
complications, as well as intensive care unit admissions [7, 8]. There is no 51 
consensus in the literature as to whether this confers an increased risk of mortality 52 
[9-13]. There have been large institutional series reports that have shown that 53 
simultaneous bilateral TKA can be performed safely without increased peri-54 
operative morbidity and mortality compared to staged bilateral TKA if a selective 55 
pre-operative screening process is used [14-16]. Same-day bilateral TKA has been 56 
reported to have benefits of decreased cost [17-19], improved recovery time [20], 57 
the use of a single anaesthetic [21], and equal functional outcomes [22]. 58 
In patients undergoing staged bilateral TKA, there is a wide range of reported 59 
recommended intervals between the first and second operation, ranging from 1 to 60 
120 months [23-25]. The indications for staged TKA and the methods of choosing 61 
the first side for operation varied between studies [26, 27]. Many comparisons 62 
were aimed at the safety, perioperative complications and cost effectiveness of 63 
simultaneous versus staged bilateral TKA, while few studies had considered 64 
subsequent revision rates. 65 
The aim of this study was to utilise data from the Australian Orthopaedic 66 
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Association National Joint Replacement Registry (AOANJRR) to investigate the 67 
implant survivorship and 30-day mortality of simultaneous bilateral TKA compared 68 
to staged bilateral TKA of various intervals. 69 
Materials and Methods 70 
The analysis for this study was undertaken by the AOANJRR. The AOANJRR is an 71 
Australian Federal Government-funded AOA initiative with the purpose of 72 
improving the care of patients undergoing joint arthroplasty, providing accurate 73 
demographic information, and establishing a reliable method of audit for both 74 
hospitals and individual surgeons [28, 29]. Data collection commenced in 75 
September 1999, with staged state-based implementation leading to full national 76 
data collection in mid-2002. 77 
Registry data is obtained at the time of surgery and includes patient details, 78 
hospital, type of procedure, joint replaced, side, diagnosis, and component details. 79 
All public and private hospitals in Australia performing joint replacement surgery 80 
provide information to the Registry. Data is validated against State Health 81 
Department separation data and this enables the AOANJRR to have a complete 82 
dataset of all joint replacement surgery. The AOANJRR dataset is matched 83 
biannually to the Australian National Death Index (Australian Institute of Health 84 
and Welfare). This enables the AOANJRR to have a complete list of patients who 85 
have died and the date of their death.  86 
The study period for this analysis was September 1, 1999 to December 31, 2015. 87 
The AOANJRR identified all bilateral primary TKA procedures undertaken for 88 
osteoarthritis (OA) within 6 months of the initial procedure. Bilateral TKA 89 
procedures were grouped into four categories: simultaneous (same-day), or staged 90 
bilateral TKA procedures with intervals of 1 day – 6 weeks, 6 weeks – 3 months and 91 
3 months – 6 months, with numbers reported at patient level.  92 
Analysis provided information on revision rates (as determined by the time to first 93 
revision of either knee from the time of second TKA), reasons for revision, 94 
cumulative incidence revision for the five most common reasons for revision, types 95 
of revision, and 30-day mortality after the second procedure . Further analysis by 96 
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age (over or under 65 years) and type of fixation (cement, cementless or hybrid) 97 
was undertaken. These analyses did not identify any differences to the overall data 98 
and have therefore not been included (data available upon request). ASA grade 99 
and BMI were available from the time they were added to the core dataset in 2012 100 
and 2015 respectively. 101 
Statistics 102 
The Kaplan Meier method was used to determine cumulative percent revision 103 
(CPR) and cumulative percent survival (CPS). Unadjusted CPR values are reported 104 
with 95% confidence interval (CI). Revision (and mortality) rates were compared 105 
using Cox proportional hazards models, adjusting for age and sex. Tests were 2-106 
tailed at the 5% level of significance. Descriptive analysis of reasons for revision 107 
and type of revision are also reported. 108 
Results 109 
There were 36,087 bilateral primary TKAs (72,174 knees) undertaken for OA with a 110 
maximum interval of six months between procedures during the study period. 111 
Specifically, there were 23,136 (64.1%) simultaneous bilateral TKA procedures and 112 
12,951 staged bilateral TKA procedures (1,262 (3.5%) 1 day – 6 weeks, 2,638 (7.3%) 113 
6 weeks–3 months, and 9,051 (25.1%) 3–6 months) (Table 1). Age, gender, ASA 114 
grade and BMI details for each group are shown in Table 1. 115 
There was no significant difference in the rate of revision when the three different 116 
interval groups of staged bilateral TKA were compared to simultaneous bilateral 117 
TKA (1 day–6 weeks) HR= 1.09 (95% CI 0.85-1.40; p=0.511), (6 weeks–3 months) 118 
HR=0.93 (95% CI 0.77-1.14; p=0.494) and (3 month–6 months) HR=1.10 (95% CI 119 
0.98-1.23; p=0.115). (Table 2, Figure 1). 120 
In the simultaneous bilateral TKA group the most common reasons for revision 121 
were loosening/lysis (29.0%), infection (23.4%) and patellofemoral pain (11.3%). 122 
The reasons for revision were similar in the staged bilateral TKA groups (Table 3, 123 
Figure 2). There was no significant difference in the revision rates for 124 
loosening/lysis or infection when the three different interval groups of staged 125 
bilateral TKA were compared to simultaneous bilateral TKA (Table 4). 126 
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The most common type of revision for simultaneous bilateral TKA was a total 127 
revision (tibial and femoral components - 25.0%), insert only - 22.6% and patella 128 
only - 17.7%). The types of revision in the staged bilateral TKA groups were similar 129 
(Table 5). 130 
The 30-day mortality (from second procedure) for the four groups of bilateral TKA 131 
procedures was 0.17% (simultaneous), 0.08% (1 day – 6 weeks), 0.04% (6 weeks – 132 
3 months) and 0.07% (3 months – 6 months) (Table 6). For comparison, the 30-day 133 
mortality rate for all primary TKAs for OA is 0.13%. Overall, when combining all 134 
staged bilaterals (1 day – 6 months), the 30-day mortality was 0.06% which was 135 
significantly lower than the simultaneous bilateral group (p=0.0004). There was a 136 
significantly lower 30-day mortality rate in the staged 6 weeks to 3 months group 137 
than for the simultaneous bilaterals (OR 0.30 (95% CI 0.13 to 0.72), p=0.007). 138 
Although the 30-day mortality rates were also lower in the other staged groups 139 
than the simultaneous bilaterals, statistically there was no significant difference (1 140 
day – 6 weeks; OR 0.46 (95% CI 0.06 to 3.33), p=0.441 and 3 months – 6 months, 141 
OR 0.19 (95% CI 0.03 to 1.39), p=0.103). Both age and ASA grade were significantly 142 
lower in the simultaneous bilateral group compared with all other groups (both 143 
p<0.001, chi-squared test). 144 
Discussion 145 
This study compared the revision rates, reasons for revision, types of revision and 146 
30-day mortality of simultaneous bilateral TKA to the three groups of staged 147 
bilateral TKA of various intervals. There was no difference in revision rate, reasons 148 
for revision or types of revision. There was a significantly lower 30-day mortality 149 
rate in the 6 weeks – 3 months staged compared with the simultaneous bilateral 150 
groups.  151 
The rate of revision between the groups in our study were similar, with no 152 
significant differences found between the simultaneous and different timed staged 153 
procedures. 154 
However, our analysis shows a significantly lower 30-day mortality rate for staged 155 
6 week – 3 months bilateral TKA despite the fact that the simultaneous bilateral 156 
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group was younger and fitter (according to ASA grade) than the other groups. It 157 
has been suggested that 30-day mortality rate provides the best measure of 158 
mortality related to TKA, as reporting of mortality beyond 30 days of the 159 
procedure may represent deaths not related to the operation [30]. Some studies 160 
have shown increased 30-day mortality rate for simultaneous bilateral TKA 161 
compared to staged bilateral TKA [31, 32] and unilateral TKA [30]. A number of 162 
more recent studies have shown no difference in 30-day mortality between 163 
simultaneous bilateral TKA and unilateral TKA [11, 13, 33, 34], which may correlate 164 
with improvement in surgical technique over time or better patient selection, 165 
although some had relatively small numbers.  166 
In 2003, Ritter et al [25] found no significant difference among the three groups of 167 
simultaneous bilateral, staged bilateral, and unilateral TKA with respect to revision 168 
or mortality rates. The 10 year CPR for simultaneous bilateral, unilateral, and 169 
staged bilateral TKA groups was 98.3% (95% CI, 97.5% - 99.1%), 97.5% (95% CI, 170 
95.4% - 99.6%), and 99.5% (95% CI, 98.6% - 100%), respectively. Our data of 171 
comparing simultaneous bilateral TKA and staged bilateral TKA of different 172 
durations echoes these findings of no significant difference in revision rates. 173 
In a 1997 study on a larger group of Medicare patients, Ritter et al [31] compared a 174 
simultaneous bilateral TKA group (12,922 patients) with groups that had staged 175 
procedures within six weeks (4354 patients), six weeks - three months (4524 176 
patients), three - six months (9829 patients), and six months - one year (31,401 177 
patients). The simultaneous bilateral TKA group had the highest cumulative 178 
mortality rate at three months postoperatively (1.47%). At one year, the group 179 
that had the staged procedure within six weeks had the highest cumulative 180 
mortality rate (2.83%). By two years postoperatively, the cumulative mortality 181 
rates for all of the groups were similar. Neither the simultaneous nor the staged 182 
bilateral TKA had a mortality advantage over the others, and it was determined 183 
that the decision about whether to attempt simultaneous or staged bilateral TKA 184 
should be made on an individual basis by the patient and the physician. In 2001, 185 
Parvizi et al [30] investigated the mortality rate within thirty days after TKA in their 186 
entire patient cohort of 22,540 patients over a 28-year period (with 2,679 – 11.9% 187 
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bilateral cases). The mortality rate within 30 postoperative days after simultaneous 188 
bilateral TKA was significantly higher (p < 0.002) than that after unilateral TKA. 189 
Previous studies have reported increased wound healing problems, and 190 
cardiopulmonary problems [35] following simultaneous bilateral TKA. There have 191 
also been reports of greater risk of complications and mortality associated with 192 
early staged bilateral TKA (within the same hospitalisation or within 3 months) [36, 193 
37]. Experts participating in the Consensus Conference on Bilateral Total Knee 194 
Arthroplasty Group in 2013 [38], made a number of consensus statements. Most 195 
(81%) agreed that if a patient was not a suitable candidate for same-day bilateral 196 
TKA, then a second TKA should be scheduled for at least 3 months or later. The 197 
vast majority (96%) opposed the idea of staging within the same hospital 198 
admission. Our findings suggest that a delay of 6 weeks may be adequate to 199 
mitigate mortality risk. 200 
Much has been discussed about perioperative complications that are associated 201 
with simultaneous bilateral TKA. Cardiac complications such as myocardial 202 
infarction, arrhythmias, and congestive cardiac failure are some of the common 203 
reported cardiac complications following simultaneous bilateral TKAs [23, 33, 39, 204 
40]. The cause of this remains unclear; however, the rates of cardiac complication 205 
are reported to be higher in patients with pre-existing comorbid medical 206 
conditions and in elderly patients (>80 years). It can be postulated that the 207 
physiological stress imposed by the simultaneous procedure on this group of high-208 
risk patients with presumed suboptimal cardiorespiratory reserve could be the 209 
cause of increased complications [41]. This may be attributed to longer length of 210 
hypotension secondary to spinal anaesthesia, larger fluid shifts, and potentially 211 
greater intraoperative hypoxia or anaemia during hospitalization. 212 
The rates of intensive care unit admission are also reported to be higher with 213 
simultaneous bilateral procedures. This might be a reflection of the greater need 214 
for monitoring of cardiopulmonary parameters with this procedure, especially in 215 
elderly patients. In a study by Bullock et al [33], the rate of intensive care unit 216 
admission was observed to be 0.59% in the unilateral group and 3.9% in the 217 
bilateral group, with a relative risk of 6.61. Similarly, Ritter et al [31] reported that 218 
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the number of intensive care unit care days of simultaneous bilateral TKA were 219 
twice that in unilateral or staged groups. 220 
The rates of blood transfusion in simultaneous bilateral TKA have also been found 221 
to be greater than those in unilateral arthroplasty groups, in varying degrees [34, 222 
42-45]. 223 
A major strength of the study is the completeness and volume of bilateral 224 
procedures analysed. The revision rate of TKA is low; therefore, large numbers are 225 
required to have sufficient statistical power to enable a meaningful comparison. 226 
This is most easily achieved using data from a large registry. Although the numbers 227 
in the subgroups of staged bilateral TKAs are comparatively low, there is a good 228 
representation across all states/territories within Australia, with relatively high 229 
numbers of surgeons (more than 200 in each group) and hospitals (more than 100 230 
in each group) represented in these groups [data not shown but available]. Most 231 
studies to date have compared safety, perioperative complications and cost of the 232 
surgeries of simultaneous bilateral TKA to staged bilateral TKA. To our knowledge, 233 
this represents the first study that has sufficient power to statistically compare 234 
revision rates.  235 
The major limitations of this study are the potential for confounding and patient 236 
selection for bilateral surgery. The risk of revision may be impacted by multiple 237 
factors including age, gender, comorbidity, type of prosthesis, surgical expertise 238 
and the perceived risk versus benefit of undertaking a revision. While it is likely 239 
that some of these factors are equally distributed across groups, it is almost certain 240 
that patients chosen to have simultaneous bilateral TKA differ from the population 241 
having staged bilateral TKA, as indicated by the lower age and ASA grade. Although 242 
the analysis is adjusted for age and gender, more detailed patient demographic 243 
data were not analysed beyond age comparison of over and under 65s, fixation 244 
and comparison of age and ASA between groups. There is selection bias of patients 245 
undergoing simultaneous bilateral TKAs who are younger, healthier, and less 246 
medically comorbid. The simultaneous bilateral group would therefore be 247 
expected to have a lower 30-day mortality rate than any other group, rather than 248 
the contrary finding in our study with a higher mortality rate than all of the other 249 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
groups. The reasons for this contrary finding are not obvious from the data 250 
available on the Registry, particularly in relation to the lower 30-day mortality in 251 
the 6 week – 3 month group, and so a plausible explanation for this would be 252 
speculation on the authors’ part. Further investigation to confirm this finding and 253 
explain it are therefore recommended. Other medical complications that do not 254 
lead to revision are also not recorded in the registry which limits the outcome used 255 
in the analysis to revision or death. There is also the likelihood that some intended 256 
bilateral patients died before the second side was performed, which would mean 257 
that the differential in 30-day mortality between the same day and staged 258 
bilaterals would be less pronounced. This may also partially account for the 259 
increased 30-day mortality rate in the unilateral TKA’s. However, this is unlikely to 260 
account for the entire difference in mortality rate. 261 
Conclusion 262 
Although there is no difference in revision rates based on the interval of the 263 
second procedure for bilateral primary TKA undertaken within 6 months, the 264 
mortality is significantly lower when bilateral procedures are staged and lowest 265 
when the interval is 6 weeks to 3 months. In spite of being younger and fitter, the 266 
simultaneous bilateral TKAs have a measurably higher 30-day mortality risk than 267 
staged surgery, and surgeons and patients need to decide on a case-by-case basis 268 
whether the elevated risk of bilateral surgery is outweighed by patient-specific 269 
benefits. . 270 
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Table and Figure Legends 
 
Table 1: Demographics for each group. Patient numbers are reported. 
Table 2: Yearly Cumulative Percent Revision of Primary Total Knee Replacement (Primary Diagnosis OA) with all 
primary TKA for OA for comparison [46].  
Table 3: Most Common Revision Diagnoses of Primary Total Knee Replacement (Primary Diagnosis OA). 
Table 4: Hazard ratios (95% CIs) of revision rates for various staged interval bilaterals compared with simultaneous 
bilaterals (with p-values) with reasons for revision of loosening/lysis or infection. 
Table 5: Type of Revision of Primary Total Knee Replacement (Primary Diagnosis OA). 
Table 6: 30-day Mortality (Cumulative Percent Survival (CPS)) following Bilateral Primary Total Knee Replacements 
by Group (Primary Diagnosis OA). 
 
Figure 1: Cumulative Percent Revision of Primary Total Knee Replacement (Primary Diagnosis OA).  
Figure 2: Cumulative Incidence Revision Diagnosis of Primary Total Knee Replacement (Primary Diagnosis OA)  
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Table 1: Demographics for each group. Patient numbers are reported. 
 Bilateral  
Same Day 
Bilateral  
1 day-6wks 
Bilateral  
6wks-3mths 
Bilateral  
3mths-6mths 
N 23136 1262 2638 9051 
     
Gender     
Male 12449 (53.8%) 691 (54.8%) 1478 (56.0%) 4388 (48.5%) 
Female 10687 (46.2%) 571 (45.2%) 1160 (44.0%) 4663 (51.5%) 
     
Age     
<55 2284 (9.9%) 152 (12.0%) 241 (9.1%) 544 (6.0%) 
55-64 8526 (36.9%) 481 (38.1%) 886 (33.6%) 2554 (28.2%) 
65-74 8979 (38.8%) 420 (33.3%) 996 (37.8%) 3628 (40.1%) 
≥75 3347 (14.5%) 209 (16.6%) 515 (19.5%) 2325 (25.7%) 
     
ASA*     
N 7000 309 726 2069 
1 777 (11.1%) 28 (9.1%) 41 (5.6%) 99 (4.8%) 
2 4531 (64.7%) 185 (59.9%) 415 (57.2%) 1104 (53.4%) 
3 1651 (23.6%) 93 (30.1%) 259 (35.7%) 842 (40.7%) 
4 41 (0.6%) 3 (1.0%) 11 (1.5%) 24 (1.2%) 
     
BMI*     
N 2626 127 245 535 
Underweight 285 (10.9%) 12 (9.4%) 33 (13.5%) 69 (12.9%) 
Normal 263 (10.0%) 6 (4.7%) 15 (6.1%) 45 (8.4%) 
Pre-Obese 775 (29.5%) 44 (34.6%) 52 (21.2%) 140 (26.2%) 
Obese Class 1 772 (29.4%) 28 (22.0%) 74 (30.2%) 106 (19.8%) 
Obese Class 2 361 (13.7%) 20 (15.7%) 37 (15.1%) 98 (19.0%) 
Obese Class 3 170 (6.5%) 17 (13.4%) 34 (13.9%) 77 (25.8%) 
     
*ASA has only been recorded for procedures since 2012; BMI has only been recorded since 2015. 
ASA and BMI are based on the first procedure. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2: Yearly Cumulative Percent Revision of Primary Total Knee Replacement (Primary Diagnosis OA) with all 
primary TKA for OA for comparison [46].  
Group N 
Revised 
N Total 1 Yr 3 Yrs 5 Yrs 7 Yrs 10 Yrs 13 Yrs 
Bilateral same day 1028 23136 1.2 (1.1, 1.4) 3.1 (2.9, 3.3) 4.4 (4.1, 4.7) 5.6 (5.2, 6.0) 7.4 (6.9, 8.0) 9.9 (9.0, 10.8) 
Bilateral 1 day–6 wk 65 1262 1.4 (0.9, 2.3) 4.0 (3.0, 5.3) 4.9 (3.7, 6.4) 6.0 (4.6, 7.8) 7.6 (5.7, 9.9) 10.5 (7.2, 15.3) 
Bilateral 6wk–3mths 108 2638 1.3 (0.9, 1.8) 2.9 (2.3, 3.7) 4.2 (3.4, 5.2) 5.1 (4.1, 6.3) 6.6 (5.3, 8.2) 7.9 (6.2, 10.0) 
Bilateral 3mths–6mths 411 9051 1.3 (1.1, 1.5) 3.3 (2.9, 3.7) 4.5 (4.0, 5.0) 5.6 (5.1, 6.3) 7.0 (6.3, 7.8) 9.0 (7.8, 10.3) 
Total 1612 36087       
All primary OA TKA* 17213 482373 
(knees) 
1.0 (1.0, 1.1) 2.7 (2.7, 2.8) 3.6 (3.6, 3.7) 4.4 (4.3, 4.4) 5.3 (5.2, 5.4) 7.3 (7.1, 7.6) 
Note: *all bilateral procedures are reported at the patient level (i.e. one patient is two knees) and so risk of revision to either knee is 
higher than for a single knee (majority of primary OA TKA) 
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Table 3: Most Common Revision Diagnoses of Primary Total Knee Replacement (Primary Diagnosis OA). 
 Bilateral Same Day Bilateral 1day-6wks Bilateral 6wks-3mths Bilateral 3mths-6mths 
Revision Diagnosis N % Revision % Primary N % Revision % Primary N % Revision % Primary N % Revision % Primary 
Loosening/Lysis 298 29.0 1.3 20 30.8 1.6 35 32.4 1.3 115 28.0 1.3 
Infection 241 23.4 1.0 15 23.1 1.2 33 30.6 1.3 132 32.1 1.5 
Patellofemoral Pain 171 16.6 0.7 11 16.9 0.9 14 13.0 0.4 57 13.8 0.7 
Instability 69 6.7 0.3 1 1.5 0.1 5 4.6 0.2 26 6.3 0.3 
Other 249 24.2 0.1 18 27.7 1.4 21 19.4 0.8 81 19.7 0.9 
N Revision 1028 100.0 4.4 65 100.0 5.2 108 100.0 4.1 411 100.0 4.5 
N Primary 23136   1262   2638   9051   
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Table 4: Hazard ratios (95% CIs) of revision rates for various staged interval bilaterals compared with simultaneous 
bilaterals (with p-values) with reasons for revision of loosening/lysis or infection. 
 Bilateral same day 
Staged interval Loosening/lysis Infection 
1 day – 6 weeks 1.13 (0.72 to 1.78), p=0.586 1.13 (0.72 to 1.78), p=0.586 
6 weeks – 3 months 1.04 (0.73 to 1.48), p=0.812 1.04 (0.73 to 1.48), p=0.812 
3 months – 6 months 1.11 (0.90 to 1.38), p=0.327 1.11 (0.90 to 1.38), p=0.327 
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Table 5: Type of Revision of Primary Total Knee Replacement (Primary Diagnosis OA). 
 Bilateral Same Day Bilateral 1day-6wks Bilateral 6wks-3mths Bilateral 3mths-6mths 
Type of Revision N % Revision % Primary N % Revision % Primary N % Revision % Primary N % Revision % Primary 
TKR (Tibial/Femoral) 257 25.0 1.1 23 35.4 1.8 31 28.7 1.2 91 22.1 1.0 
Insert Only 232 22.6 1.0 12 18.5 1.0 24 22.2 0.9 109 26.5 1.2 
Patella Only 182 17.7 0.8 13 20.0 1.0 22 20.4 0.8 63 15.3 0.7 
Insert/Patella Patella 
Only 
118 11.5 0.5 6 9.2 0.5 3 2.8 0.1 32 7.8 0.4 
Tibial Component 100 9.7 0.4 4 6.2 0.3 12 11.1 0.5 51 12.4 0.6 
Femoral Component 71 6.9 0.3 3 4.6 0.2 4 3.7 0.2 18 4.4 0.2 
Cement Spacer 59 5.7 0.3 4 6.2 0.3 11 10.2 0.4 42 10.2 0.5 
Removal of Prostheses 4 0.4 0.0    1 0.9 0.0 3 0.7 0.0 
Insert Only Minor 
Components* 
1 0.1 0.0          
Insert/Patella Insert 
Only* 
1 0.1 0.0          
Minor Components 1 0.1 0.0       1 0.2 0.0 
N Revision 1028 100.0 4.4 65 100.0 5.2 108 100.0 4.1 411 100.0 4.5 
N Primary 23136   1262   2638   9051   
Note: *Same day primary bilateral patients revised on the same day. Both types of revision are listed. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 6: 30-day Mortality (Cumulative Percent Survival (CPS)) following Bilateral Primary Total Knee Replacements 
by Group (Primary Diagnosis OA). 
Group 
N Death 
(30 day) 
N Patients 
% 30-day 
Deaths 
30-day CPS 
Logistic regression 
(age/gender 
adjusted) p-value 
Bilateral Same Day 40 23,136 0.17 99.9 (99.4, 100.0) Reference 
Bilateral 1day-6wks 1 1262 0.08 99.9 (99.9, 100.0) p=0.441 
Bilateral 6wks-3mths 1 2638 0.04 99.9 (99.7, 100.0) p=0.007 
Bilateral 3mths-6mths 6 9051 0.07 99.8 (99.8, 99.9) p=0.103 
All staged 1 day-
6mths 
8 12,951 0.06 99.9 (99.8, 100.0) p=0.0004 
TOTAL 48 36,087 0.13   
All primary OA TKA 629 
482,373 
(knees) 
0.13 99.9 (99.8, 99.9) p=0.095 
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Figure 1: Cumulative Percent Revision of Primary Total Knee Replacement (Primary Diagnosis OA).  
 
 
Number at Risk 0 Yr 1 Yr 5 Yrs 8 Yrs 10 Yrs 13 Yrs 15 Yrs 
Bilateral Same Day 23136 20028 10302 5358 3044 791 91 
Bilateral 1day-6wks 1262 1109 626 349 196 50 9 
Bilateral 6wks-3mths 2638 2285 1203 650 377 101 3 
Bilateral 3mths-6mths 9051 7983 4339 2328 1331 301 17 
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Figure 2: Cumulative Incidence Revision Diagnosis of Primary Total Knee Replacement (Primary Diagnosis OA)  
 
 
 
 
